Navigation Links
Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO
Date:3/11/2008

ytotoxic to a human colon cancer cell line in vitro through induction of oncotic cell death, a form of cell death characterized by cell and organelle swelling and loss of membrane integrity; second, the antibody mediates antibody-dependent cellular cytotoxicity; third, the antibody mediates complement dependent cell killing; and finally, the antibody alters cellular signaling required for cell survival. RAV12 is highly efficacious in human colon, gastric, and pancreatic tumor xenograft models in vivo and has been found to be well tolerated in repeat dose primate toxicology studies.

About Raven

Raven biotechnologies, inc. (http://www.ravenbio.com) is a privately held biotechnology company focused on the development of monoclonal antibody therapeutics for treating cancer. Raven's lead product candidate, RAV12, targets adenocarcinomas and is in clinical development for the treatment of gastrointestinal and other cancers. Raven's discovery process simultaneously identifies cell-surface drug targets and the antibody therapeutics to regulate them. Our focus on biological function allows us to rapidly identify novel target antigens and therapeutic candidates in their native configuration in the intact cell membrane. Our integrated approach is based on proprietary methods for optimizing the production of MAbs targeting cell-surface proteins, including the use of human tissue-specific progenitor and tumor stem cell lines developed at Raven.

To date Raven has identified multiple candidate therapeutic MAbs for many cancer indications including lung, colon, pancreatic, prostate, breast, brain, and ovarian cancer.

On November 12, 2007, Raven and VaxGen Inc. (Pink Sheets: VXGN.PK), a biopharmaceutical company, announced that their respective boards of directors unanimously approved a definitive merger agreement. The merger is expected to create a drug development company with a robust pipeline of mono
'/>"/>

SOURCE Raven biotechnologies, inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
2. Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations
3. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
4. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
5. First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
6. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
7. Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim
8. Cynosure Announces Upcoming Investor Presentations at Cowen and Citi Investor Conferences
9. Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
10. Mentice AB Announces Leadership Changes Within Its Worldwide Operations
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... device," Nobel laureate Herbert Kroemer famously observed, referring ... the junctures where layers of different materials meet. ... between layers of metal oxides are becoming increasingly ... spintronics, high-temperature superconductors, ferroelectrics and multiferroics. Realizing the ...
(Date:1/15/2014)... 15, 2014 Cynvenio, a cancer diagnostics ... the genomic analysis of tumor cells in the bloodstream, ... web-based cancer decision support application powered by CollabRx, Inc. ... ClearID™ genomic test, Therapy Finder will provide breast cancer ...
(Date:1/15/2014)... More than 5 million Americans are currently ... seniors will die with Alzheimer’s or another dementia, according ... shocked many Americans into looking for ways to improve ... age-related cognitive disorders. Jonathan Weisman, president of Biohack Pure, ...
(Date:1/15/2014)... 15, 2014 Freeslate, Inc ., ... announced that Lupin Limited, one of India’s top five ... Protégé PharmD System for high throughput solid form ... focused on a wide range of quality, affordable generic ...
Breaking Biology Technology:A deeper look at interfaces 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... 26 Bionovo, Inc.,(Nasdaq: BNVI ) (the "Company") today ... of common stock at a price to the public of,$2.50 ... stock,at $3.50 per share at a price of $0.10 per ... to purchase up to an additional 15% of,the offering to ...
... - International Call for Patient Group Task ... international research, including the views of bodies that,represent ... today in,Dublin, Ireland - one of the world,s ... campaigner has called for patient,groups across Europe to ...
... Sunesis,Pharmaceuticals, Inc. (Nasdaq: SNSS ), a ... that,management will hold an investor conference call on ... PT to discuss financial results for the,third quarter ... the call via (888),297-0358 (U.S. and Canada) or ...
Cached Biology Technology:Bionovo Announces the Pricing of Public Offering of Shares of Common Stock 2Bionovo Announces the Pricing of Public Offering of Shares of Common Stock 3Patients Fail to Take Fake Medicines Risk Seriously 2Patients Fail to Take Fake Medicines Risk Seriously 3
(Date:4/17/2014)... new early-warning signs of the potential loss of sight ... for the diagnosis and treatment of diabetic retinopathy, potentially ... "We had not expected to see such striking changes ... Elsner, professor and associate dean in the IU School ... set out to study the early signs, in volunteer ...
(Date:4/17/2014)... wild animals and plant life, but there,s an invisible ... in the soil, decomposing organic matter and releasing carbon ... fungi play in ecological systems, their identities have only ... generated a genetic map of more than 10,000 species ... this week in the Proceedings of the National ...
(Date:4/17/2014)... View of Domestication," a special feature of The ... ( PNAS ) published April 29, raises a ... deep history that most of us take for granted. ... in many spots around the globe shifted from hunting ... and plants. , It seems so straightforward and yet ...
Breaking Biology News(10 mins):New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3Stanford biologists help solve fungal mysteries 2Stanford biologists help solve fungal mysteries 3Genetic study tackles mystery of slow plant domestications 2Genetic study tackles mystery of slow plant domestications 3Genetic study tackles mystery of slow plant domestications 4
... August 8th, 2011, Shenzhen, China BGI, the ... Shenzhen Second People,s Hospital, announced today that the study ... cell carcinoma (TCC) of the bladder was published online ... valuable genetic basis for future studies on TCC, suggesting ...
... WEST LAFAYETTE, Ind. -- A Purdue University scientist is urging ... allowed for U.S. consumption and arguing that not doing so ... William Muir, a professor of animal sciences, said that based ... Administration, AquAdvantage (AA) salmon poses little real risk to the ...
... is currently used as a component of intravenous nutrition and ... protection for patients suffering from heart attacks. Current ... of the ischemic period, when blood flow to tissues is ... blood flow. It is well known that injury to the ...
Cached Biology News:Research discovers frequent mutations of chromatin remodeling genes in TCC of the bladder 2Scientist urges government ruling on genetically engineered salmon 2Scientist urges government ruling on genetically engineered salmon 3
... Technology's family of light scattering instruments. The ... chromatograph and enables you to get multi-angle ... HTmD is easily installed in the oven ... 2000 device and enables you to get ...
...
... Experion HighSens reagents and supplies, for ... supplies sufficient to perform high-sensitivity RNA ... on the Experion automated electrophoresis system. ... 20 microliters RNA HighSens stain, 20 ...
MAb to Verotoxin II (SLT-2a) Verotoxin II (Shiga-like) A subunit (SLT-2a)...
Biology Products: